Mobel Biocare

SEP 2 7 2002

Section 1.7

510(k) Summary

Establishment Information

Nobel Biocare USA, Inc. 22715 Savi Ranch Parkway Yorba Linda, CA 92887

USA

Telephone:

(800) 993-8100, ext 7830

FAX:

(714) 998-9348

Contact

Richard T. Ross, RAC

Senior Regulatory Affairs Specialist Telephone: (714) 282-4800, ext. 7830

Proprietary device name

Replace™ HA Coated Implant (K020646)

Classification

name

Endosseous Dental Implant (21 CFR 872.3640)

Device

classification

Class III

Statement

The information supporting claims of substantial equivalence, as defined under the Federal Food, Drug, and Cosmetic Act, respecting safety and effectiveness is summarized below.

Device description

The Replace [™] HA Coated Implant is to serve as a support for prosthetic devices to restore a patient's chewing function. The available diameters are 3.5 mm, 4.3 mm, 5.0 mm and 6.0 mm with lengths of 10 mm, 13 mm, and 16 mm. The titanium alloy implant has an HA coating on the root form portion to within approximately 2 mm of the top.

Intended use

The intended use of the Replace HA Coated Implants is for restoring chewing function by serving as anchorage for dental restorations.

Indications for use

The Replace HA Coated Implant is both for single-stage or two-stage surgical procedures and cement or screw retained restorations. The Replace HA Coated Implant is intended for immediate placement and function on single tooth and/or multiple tooth applications in good quality bone (type I or type II bone), to restore chewing function. Multiple tooth applications may be splinted with a bar.

Technological characteristics

The technological characteristics of the Replace HA Coated Implants remained unchanged. No design modification was made.

Performance data

Clinical results show that the expanded Indications for Use is as safe and effective as the original Indications for Use.

Conclusion

Based on the 510(k) summaries, 510(k) statements and the information provided herein, we conclude that the expanded Indications for Use is substantially equivalent to the currently marketed device under the Federal Food, Drug, and Cosmetic Act.

DEPARTMENT OF HEALTH & HUMAN SERVICES



SEP 2 7 2002

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Karon Morell Director, Regulatory Affairs and Quality Assurance Nobel Biocare USA, Incorporated 22715 Savi Ranch Parkway Yorba Linda, California 92887

Re: K022424

Trade/Device Name: Replace™ HA Coated Implant

Regulation Number: 872.3640

Regulation Name: Endosseous Dental Implant

Regulatory Class: III Product Code: DZE Dated: July 24, 2002 Received: July 24, 2002

Dear Ms. Morell:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours

Timothy A. Ulatowski

Director

Division of Anesthesiology, General Hospital.
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use Statement

Page 1 of 1

510(k) Number (if known):]	Not yet assigned —	K022424
	[™] HA Coated Impl	
Indications for Use:		
and cement or screw retained refor immediate placement and the	restorations. The R function on single to type II bone), to re	e-stage or two-stage surgical procedures eplace HA Coated Implant is intended ooth and/or multiple tooth applications estore chewing function. Multiple tooth
(PLEASE DO NOT WRITE BELOV	W THIS LINE - CONT	INUE ON ANOTHER PAGE IF NEEDED)
Concurrence of	f CDRH, Office of I	Device Evaluation (ODE)
Prescription Use	OR	Over-the-Counter Use

(Division Sign-Off)
Division of Anesthesiology, General Hospital,
Infection Control, Dental Devices